Abstracts tagged "Comorbidity"

Abstract Number: 1987 • ACR Convergence 2022
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
CF Allaart¹, Sytske Anne Bergstra², Tom Huizinga¹ and Joy van der Pol³, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Utrecht, Netherlands
Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…
Abstract Number: 0255 • ACR Convergence 2022
Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?
Yosuke Kunishita¹, Kayo Harita², Chikara Honda², Masaki Mitsuhasi² and Shouhei Nagaoka², ¹Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Kanagawa, Japan, ²Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan
Background/Purpose: In 2019, a study based on post-marketing surveillance data in Japan reported that abatacept (ABT) was as effective and safe in elderly patients with…
Abstract Number: 1605 • ACR Convergence 2022
Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study
Bas Dijkshoorn¹, Daisy Vedder¹, Anna Rudin², Dan Nordstrom³, Bjorn Gudbjornsson⁴, Kristina Lend⁵, Till Uhlig⁶, Espen Haavardsholm⁶, Gerdur Maria Grondal⁷, Merete L Hetland⁸, Marte Heiberg⁶, Mikkel Østergaard⁹, Kim Horslev-Petersen¹⁰, Jon Lampa¹¹, Ronald van Vollenhoven¹², Aleksandra antovic¹³ and Michael Nurmohamed¹⁴, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ³Helsinki University Hospital, Helsinki, Finland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵The Karolinska Institute, Stockholm, Sweden, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Landspitali University Hospital, Centre for Rheumatology Research, Reykjavik, Iceland, ⁸Rigshospitalet, Glostrup, Denmark, ⁹Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ¹⁰Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ¹¹Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Karolinska Institute, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹⁴Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of venous thromboembolism. Thus far, there have not been any comparative studies investigating the…
Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Tanya Shivacheva, Medical University prof.dr. P. Stoyanov, Varna, Bulgaria, Varna, Bulgaria
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…
Abstract Number: 0259 • ACR Convergence 2022
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
Ju Yeon Kim¹, Kichul Shin², Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic…
Abstract Number: 1609 • ACR Convergence 2022
Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort
Paras Karmacharya¹, Cynthia Crowson², Ryan Lennon³, Dilli Poudel⁴, John Davis³, Alexis Ogdie⁵, Jean Liew⁶, Michael Ward⁷, Mariko Ishimori⁸, Michael Weisman⁹, Matthew Brown¹⁰, Mohammad Rahbar¹¹, Mark Hwang¹², John Reveille¹³ and Lianne Gensler¹⁴, ¹Vanderbilt University, Nashville, TN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN, ⁴Indiana Regional Medical Center, Indiana, PA, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Boston University, Boston, MA, ⁷National Institutes of Health, Rockville, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Genomics England, London, United Kingdom, ¹¹University of Texas Health Science Center at Houston, Houston, TX, ¹²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ¹³University of Texas McGovern Medical School, Houston, TX, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Comorbidities occur more frequently in patients with ankylosing spondylitis (AS) than in the general population and are associated with higher morbidity and mortality. Some…
Abstract Number: 2009 • ACR Convergence 2022
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
Manami Nomura¹, Takahiko Sugihara², Hiroyuki Baba¹, Tatsuro Ishizaki³, Tadashi Hosoya¹, Mari Kamiya¹, Takumi Matsumoto², Kanae Kubo⁴, Fumio Hirano⁵, Masayo Kojima⁶, Nobuyuki Miyasaka⁵, Shinsuke Yasuda⁵ and Masayoshi Harigai⁷, ¹Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ³Human Care Research Team, Tokyo Metropolitan Institute of Gerontology., Tokyo, Japan, ⁴Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Department of Frailty Research, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Nagoya, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) tend to have a higher risk for drug-related adverse events (AEs) than younger patients, and the effectiveness and…
Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Evgeny Nasonov¹, Eugen Feist², Michael Luggen³, Sergey Yakushin⁴, Daria Bukhanova⁵, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁵ and Josef Smolen⁷, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, ⁵R-Pharm JSC, Moscow, Russia, ⁶R-Pharm, Moscow, Russia, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…
Abstract Number: 1637 • ACR Convergence 2022
Association of Dermatomyositis with Cardiovascular Disease: A Case-Control Study in the All of Us Research Program
Jill Shah¹, Keya Shah², Daniel Mazori¹, Avrom Caplan¹, Emily Hejazi¹ and Alisa Femia¹, ¹Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, NY, ²Department of Medicine, NYU Langone Hospital - Long Island, Mineola, NY
Background/Purpose: Previous studies on the association of dermatomyositis (DM) with cardiovascular (CV) disease have used combined idiopathic inflammatory myositis cohorts, included only non-United States (US)…
Abstract Number: 2080 • ACR Convergence 2022
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
Rashmi Dhital¹, Monica Guma², Brian Pedersen¹, Ashbina Pokharel³ and Kenneth Kalunian⁴, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³William Beaumont Hospital, Royal Oak, MI, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits…
Abstract Number: 0387 • ACR Convergence 2022
Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
Marta Ibañez Martinez¹, Sonia Pastor Navarro², Olga Compán Fernández², Belén Miguel Ibáñez², Ana Isabel Turrión Nieves², Susana Gómez Castro¹, Olga Martínez González², Cristina Hidalgo Calleja², Esther Toledano Martinez³ and Carlos Montilla Morales², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To evaluate the quality of sleep in patients with psoriatic arthritis (PsA) and its relationship with/to clinical variables, activity, functionality, the impact of the…
Abstract Number: 1643 • ACR Convergence 2022
Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK
Subhashisa Swain¹, Carol Coupland², Anne Kamps³, Jos Runhaar⁴, Andrea Dell ‘Isola⁵, Aleksandra Turkiewicz⁵, Danielle E Robinson¹, Victoria Y Strauss¹, Christian Mallen⁶, Chang-Fu Kuo⁷, Aliya Sarmanova⁸, Daniel Prieto Alhambra¹, Martin Englund⁵, Sita Bierma-Zeinstra³, Michael Doherty² and Weiya Zhang², ¹University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Erasmus University Medical Centre, Rotterdam, Netherlands, ⁴Erasmus Medical Center, Rotterdam, Netherlands, ⁵Lund University, Lund, Sweden, ⁶Keele University, Keele, United Kingdom, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Bristol, Bristol, United Kingdom
Background/Purpose: People with osteoarthritis (OA) often have multiple other conditions (comorbidities).Role of different oral analgesics on the development of comorbidities in people with OA have…
Abstract Number: 2091 • ACR Convergence 2022
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa Parra¹, Jose Meade Aguilar¹, Cynthia Crowson², Cassondra Hulshizer¹, Tina Gunderson¹, Alanna Chamberlain¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: As the life expectancy of patients with systemic lupus erythematosus (SLE) improves, comorbidities have become more critical. Multimorbidity (MM2+) is defined as the coexistence…
Abstract Number: 0697 • ACR Convergence 2022
Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?
Theodore Pincus¹, Kathryn Gibson², Juan Schmukler¹, Tengfei Li³ and Joel Block¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Fibromyalgia (FM) and depression (DEP) are common comorbidities of all reported primary rheumatic diagnoses, easily recognized in many patients, but often underestimated, particularly in…
Abstract Number: 1645 • ACR Convergence 2022
Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis
Mehreen Soomro¹, Michael Stadler¹, Sebastien Viatte¹, Alex Macgregor², Suzanne Verstappen¹, Anne Barton¹ and John Bowes¹, ¹The University of Manchester, Manchester, United Kingdom, ²The University of East Anglia, Norwich, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.